Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Inclusion Criteria:

• Ability to understand and the willingness to sign informed consent prior to anystudy- related procedures.

• Patients diagnosed with lymphoma.

• Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do notneed to be within a certain timeframe from diagnosis.

• Aged ≥18 years; due to the rarity of the disease in those <18 years, this agebracket will not be included.

• Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.

• Have physician clearance to participate in exercise.

• Speak English.

• Willing to travel to Dana-Farber Cancer Institute for necessary data collection andexercise sessions.

• Access to a phone that can receive text messages.

Exclusion Criteria:

• Unstable comorbidities that prevent participation in moderate-to-vigorous intensityexercise. Patients with unstable comorbidities likely require supervised exercisefor safety, and part of this study involves unsupervised exercise; therefore, forsafety reasons, these persons are excluded.

• Participate in more than 60 minutes of structured moderate-to-vigorous exercise perweek over the last month. Excess additional exercise is a confounding factor inassessing the effect of the current interrupted sedentary time intervention.

• Patients receiving treatment for other active malignancies (except basal cellcarcinoma). This study is exclusively targeting lymphoma chemotherapy-relatedeffects.

• Subjects who in the opinion of the investigators may not be able to comply with thesafety monitoring requirements of the study.

• Unable to travel to DFCI Longwood campus for necessary data collection andchemotherapy infusions.